Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome

[1]  K. Müller-Vahl,et al.  Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study , 2019, Front. Neurol..

[2]  B. Lutz,et al.  Plasma Parameters of the Endocannabinoid System Are Unaltered in Fibromyalgia , 2018, Psychotherapy and Psychosomatics.

[3]  Beat Lutz,et al.  Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls[S] , 2017, Journal of Lipid Research.

[4]  K. Müller-Vahl,et al.  Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients , 2017, International journal of molecular sciences.

[5]  P. Sandor,et al.  Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome. , 2017, The Journal of neuropsychiatry and clinical neurosciences.

[6]  A. S. Kanaan,et al.  Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols , 2017, Brain sciences.

[7]  A. Sartorius,et al.  Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study , 2017, European Archives of Psychiatry and Clinical Neuroscience.

[8]  N. Volkow,et al.  Don't Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward. , 2017, Annual review of pharmacology and toxicology.

[9]  M. Pirmohamed,et al.  A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  R. Bird,et al.  Severe motor and vocal tics controlled with Sativex® , 2016, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[11]  P. Asherson,et al.  Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial , 2016, European Neuropsychopharmacology.

[12]  J. Fernández-Ruiz,et al.  Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia , 2016, British journal of pharmacology.

[13]  Ethan B. Russo.  Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes , 2016, Cannabis and cannabinoid research.

[14]  G. Schelling,et al.  Reductions in circulating endocannabinoid 2-arachidonoylglycerol levels in healthy human subjects exposed to chronic stressors , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  V. Cinquina,et al.  Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease , 2015, Neuroscience Letters.

[16]  B. Lutz,et al.  Tricks and Tracks in the Identification and Quantification of Endocannabinoids , 2013 .

[17]  H. Singer.  The Neurochemistry of Tourette Syndrome , 2013 .

[18]  M. Edwards,et al.  Environmental factors in Tourette syndrome , 2013, Neuroscience & Biobehavioral Reviews.

[19]  Yiyun Huang,et al.  Elevated Brain Cannabinoid CB1 Receptor Availability in Posttraumatic Stress Disorder: A Positron Emission Tomography Study , 2013, Molecular Psychiatry.

[20]  T. Rubino,et al.  Sexually Dimorphic Effects of Cannabinoid Compounds on Emotion and Cognition , 2011, Front. Behav. Neurosci..

[21]  Mauro Maccarrone,et al.  Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[22]  M. Marciani,et al.  Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy , 2010, Epilepsia.

[23]  P. Falkai,et al.  Oral &Dgr;9-Tetrahydrocannabinol Improved Refractory Gilles de la Tourette Syndrome in an Adolescent by Increasing Intracortical Inhibition: A Case Report , 2010, Journal of clinical psychopharmacology.

[24]  S. Rossi,et al.  ALTERED ANANDAMIDE DEGRADATION IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER , 2009, Neurology.

[25]  J. Fernández-Ruiz.  The endocannabinoid system as a target for the treatment of motor dysfunction , 2009, British journal of pharmacology.

[26]  H. Critchley,et al.  The Gilles de la Tourette Syndrome–Quality of Life Scale (GTS-QOL) , 2008, Neurology.

[27]  P. Calabresi,et al.  Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  D. Centonze,et al.  Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum , 2008, Nature Neuroscience.

[29]  P. Calabresi,et al.  Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure , 2007, Neuropsychopharmacology.

[30]  J. Piacentini,et al.  Premonitory Urge for Tics Scale (PUTS): Initial Psychometric Results and Examination of the Premonitory Urge Phenomenon in Youths with Tic Disorders , 2005, Journal of developmental and behavioral pediatrics : JDBP.

[31]  P. Calabresi,et al.  A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission , 2004, Neuropsychopharmacology.

[32]  M. Nöthen,et al.  Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[33]  J. Ramos,et al.  Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence , 2004, Brain Research.

[34]  R. Buchert,et al.  [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients , 2004, Biological Psychiatry.

[35]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[36]  H. Emrich,et al.  Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. , 2003, The Journal of clinical psychiatry.

[37]  P. Wender,et al.  [Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults]. , 2002, Der Nervenarzt.

[38]  H. Emrich,et al.  Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial , 2002 .

[39]  T. Bisogno,et al.  Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. , 2001, European journal of pharmacology.

[40]  J. Chambers,et al.  The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) , 2000, British journal of pharmacology.

[41]  H. Emrich,et al.  Cannabinoids: possible role in patho‐physiology and therapy of Gilles de la Tourette syndrome , 1998, Acta psychiatrica Scandinavica.

[42]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[43]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. , 1989, Archives of general psychiatry.

[44]  D. Cohen,et al.  The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.

[45]  N. Szejko,et al.  Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome - case report , 2018 .

[46]  B. Lutz,et al.  Extraction and Simultaneous Quantification of Endocannabinoids and Endocannabinoid-Like Lipids in Biological Tissues. , 2016, Methods in molecular biology.

[47]  Masahiko Watanabe,et al.  Endocannabinoid-mediated control of synaptic transmission. , 2009, Physiological reviews.

[48]  H. Emrich,et al.  Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. , 2002, Pharmacopsychiatry.